Cardiovascular risk: Are all NSAIDs alike?

Canadian Pharmacists Journal

Volumn 146, Issue 2, 2013, Pages 80-83

  Pawlosky, Nadia ^a  

^a ROYAL JUBILEE HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DICLOFENAC; ETORICOXIB; IBUPROFEN; LUMIRACOXIB; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; ROFECOXIB; THROMBOXANE;

ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DEATH; FOLLOW UP; GASTROINTESTINAL TOXICITY; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; META ANALYSIS (TOPIC);

EID: 84880493296     PISSN: 17151635     EISSN: 1913701X     Source Type: Journal    
DOI: 10.1177/1715163513481569     Document Type: Article

References (16)

1. NSAID-induced gastrointestinal adverse effects. In: Drug consults [intranet database]. Version 2.0. Greenwood Village (CO): Thomson Healthcare. Available: www.thomsonhc.com (accessed Sept. 19, 2011).
2. Rostom A, Moayyedi P, Hunt R; Canadian Association of Gastroenterology Consensus Group. Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks. Aliment Pharmacol Ther 2009;29:481-96.
3. e-CPS. Ottawa (ON): Canadian Pharmacists Association; 2007. Available: www.e-cps.ca (accessed Sept. 19, 2011).
4. Buye LM, Elliot ME. Osteoarthritis. In: DiPiro JT, Talbert RL, Yee GC, et al., editors. Pharmacotherapy: a pathophysiologic approach. 8th ed. Toronto (ON): McGraw- Hill; 2011.
5. Salpeter SR, Gregor P, Ormiston TM, et al. Meta-analysis: cardiovascular events associated with nonsteroidal anti- inflammatory drugs. Am J Med 2006;119:552-9.
6. Farkouh ME, Greenberg BP. An evidence-based review of the cardiovascular risks of nonsteroidal anti-inflammatory drugs. Am J Cardiol 2009;103:1227-37.
7. Bresalier RS, Sandler RS, Quan H. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1-11.
8. Trelle S, Reichenbach S, Wandel S, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 2011;342:c7086.
9. Ray WA, Varas-Lorenzo C, Chung CP, et al. Cardiovascular risks on nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease. Circ Cardiovasc Qual Outcomes 2009;2:155-63.
10. Bueno H, Bardaji A, Patrignani P, et al. Use of non- steroidal anti-inflammatory drugs and type-specific risk of acute coronary syndrome. Am J Cardiol 2010;105:1102-6.
11. Kerr DJ, Dunn JA, Langman MJ, et al. Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer. N Engl J Med 2007;357:360-9.
12. NSAID (Nonselective)/Salicylates. In: LexicompOnline Interaction Monograph [intranet database]. Hudson (OH): Lexi-Comp, Inc.; 2011. Available: http://online.lexi.com (accessed Sept. 19, 2011).
13. Aspirin. In: DRUGDEX System [intranet database]. Version 2.0. Greenwood Village (CO): Thomson Reuters (Healthcare). Available: www.thomsonhc.com (accessed Sept. 19, 2011).
14. Agency for Healthcare Research and Quality. Heart attack risks, pain relief similar for most osteoarthritis drugs. Media Release: September 26, 2006. Available: http://archive.ahrq.gov/news/press/pr2006/nsaidpr.htm (accessed July 15, 2011).
15. Solomon SD, Wittes J, Finn PV, et al. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials. Circulation 2008;117:2104-13.
16. Lanas A, Tornero J, Zamorano JL. Assessment of gastrointestinal and cardiovascular risk in patients with osteoarthritis who require NSAIDs: the LOGICA study. Ann Rheum Dis 2010;69:1453-8.